放疗后前列腺癌局部复发的单纯局部挽救治疗:系统综述与荟萃分析
汇总2年和5年无ADT生存率分别为76.8%和55.2%,无转移生存率分别为90.4%和75.2%,严重不良事件发生率因治疗方式而异。
要点
- 单纯局部挽救治疗在精心选择的放疗后局部复发前列腺癌患者中具有合理疗效。
- 汇总2年无ADT生存率为76.8%,5年为55.2%;2年无转移生存率为90.4%,5年为75.2%。
- 严重或更差不良事件发生率:LDR-BT 14%、sRP 13%、HDR-BT 5%、HIFU 5%、SBRT 4%、冷冻治疗2%。
核心结论
- 在精心选择的放疗后局部复发前列腺癌患者中,单纯局部治疗具有合理疗效,超过四分之三的患者在2年时维持无ADT生存,超过一半在5年时维持。
- 约十分之一患者出现早期转移事件,严重毒性反应可控,尤其是挽救性HDR-BT、HIFU、SBRT和冷冻治疗。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase、Web of Science核心合集和Google Scholar自建库至2025年5月,无日期或语言限制。
- 采用随机效应模型汇总无ADT生存期、无转移生存期和不良事件发生率,个体患者数据从Kaplan-Meier曲线重建或向作者获取。
主要发现
- 汇总2年和5年无ADT生存率(2887例)分别为76.8%和55.2%。
- 汇总2年和5年无转移生存率(3425例)分别为90.4%和75.2%。
- 严重或更差不良事件发生率(2308例):LDR-BT 14%、sRP 13%、HDR-BT 5%、HIFU 5%、SBRT 4%、冷冻治疗2%。
临床怎么用
- 对于放疗后局部复发且希望避免ADT相关不良事件的前列腺癌患者,可考虑单纯局部挽救治疗。
- 选择治疗方式时需结合疗效与毒性谱,HDR-BT、HIFU、SBRT和冷冻治疗的严重毒性发生率较低。
局限性
- 缺乏随机对照试验。
- 偏倚风险主要涉及患者选择。
- 前瞻性研究仅占约四分之一证据(1055例),且sRP无前瞻性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Standard-of-care management of radiorecurrent prostate cancer (PCa) involves systemic therapy; however, some patients seek to avoid the adverse events (AEs) that are associated with androgen-deprivation therapy (ADT). OBJECTIVE: To determine outcomes of local therapy without systemic therapy for radiorecurrent PCa. DATA SOURCES: MEDLINE, Embase, Web of Science Core Collection, and Google Scholar were searched from inception up to May 2025. No date or language filters were used. Data were analyzed from June to November 2025. STUDY SELECTION: Prospective and retrospective studies were selected that investigated local salvage therapies without concomitant systemic treatment for locally recurrent PCa after definitive radiotherapy. Eligible studies provided ADT-free survival (ADT-FS) and/or metastasis-free survival (MFS). Authors were contacted for additional data. DATA EXTRACTION AND SYNTHESIS: This study was prospectively registered and adhered to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Risk of bias was assessed using Risk of Bias Assessment Tool for Nonrandomized Studies, version 2. Individual patient data were reconstructed from Kaplan-Meier curves or retrieved from authors. ADT-FS, MFS, and rates of AEs were pooled in a random-effects models. MAIN OUTCOMES AND MEASURES: Main outcomes were ADT-FS and MFS, which were modeled as pooled summary Kaplan-Meier curves, and rates of severe or worse AEs, which were modeled as proportions. Outcomes were stratified by treatment method. RESULTS: Thirty-one studies (4525 patients) were identified that assessed salvage high-dose-rate brachytherapy (HDR-BT; 336 patients), low-dose-rate brachytherapy (LDR-BT; 92 patients), stereotactic body radiotherapy (SBRT; 213 patients), radical prostatectomy (sRP; 1476 patients), cryotherapy (1621 patients), high-intensity focused ultrasonography (HIFU; 677 patients), or mixed methods (110 patients). Prospective studies comprised approximately one-fourth of the evidence (1055 patients); however, none were identified for sRP. Pooled 2-year and 5-year ADT-FS (2887 patients) were 76.8% and 55.2%, respectively. Pooled 2-year and 5-year MFS (3425 patients) were 90.4% and 75.2%, respectively. Rates of severe or worse AEs (2308 patients) ranged from 14% for LDR-BT, 13% for sRP, 5% for HDR-BT, 5% for HIFU, 4% for SBRT, and 2% for cryotherapy. Risk of bias concerns primarily regarded patient selection. Limitations included a lack of randomized clinical trials. CONCLUSIONS AND RELEVANCE: The findings of this systematic review and meta-analysis suggest that local therapies alone have reasonable efficacy in well-selected patients with locally radiorecurrent PCa. ADT-free survival was maintained for more than three-quarters of patients at 2 years and more than half at 5 years. Approximately one in ten experience an early metastatic event. Rates of severe toxic effects were manageable, in particular for salvage HDR-BT, HIFU, SBRT, and cryotherapy.
引用
- Miszczyk M, Mastroleo F, Kujawska A, et al. Local Salvage Therapy Alone for Local Recurrence of Prostate Cancer After Radiotherapy: A Systematic Review and Meta-Analysis. JAMA Oncol. 2026. PMID: 42060279. doi:10.1001/jamaoncol.2026.1023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。